Executive Change

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of report (Date of earliest event reported):  December 3, 2020 Johnson & Johnson  (Exact name of registrant as specified in its charter)    New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey    08933   (Address of Principal Executive Offices)  (Zip Code)  Registrant's telephone number, including area code: 732 - 524-0400   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  ☐             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  ☐             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17                CFR 240.14d-2(b))  ☐             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17                CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).     Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 0.250% Notes Due January 2022 JNJ22 New York Stock Exchange 0.650% Notes Due May 2024 JNJ24 New York Stock Exchange 5.50% Notes Due November 2024 JNJ24BP New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange       Item 5.02(d). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Johnson & Johnson (the "Company") announced on December 3, 2020, that Dr. Nadja West, retired United States Army lieutenant general and former United States Army Surgeon General, has been appointed to its Board of Directors (the "Board"), effective immediately. Dr. West will serve as a member of the Board’s Science, Technology & Sustainability Committee, effective as of January 1, 2021. As a non-employee Director of the Company, Dr. West will receive compensation as described in the “Director Compensation” section of the Company's 2020 Proxy Statement. The Company's press release announcing the appointment is attached to this Report as Exhibit 99.1. Item 9.01. Exhibits (d) Exhibits. Exhibit No.     Description of Exhibit 99.1         Johnson & Johnson Press Release dated December 3, 2020.   SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     Johnson & Johnson        (Registrant)         Date:  December 3, 2020 By: /s/ Matthew Orlando       Matthew Orlando Corporate Secretary